The ACMD are inviting relevant stakeholders to provide submissions of written evidence to support its workstream on cognition enhancers (also known as ‘nootropics’, or study drugs).
The workstream aims to explore the prevalence, patterns and motivations for the use of cognition enhancers in the UK. The workstream will focus on, but not be limited to, the drugs modafinil, methylphenidate and dexamfetamine, and the harms to those who use these drugs outside of prescribed medical use.
If you would like to submit written evidence please get in touch with the ACMD Secretariat at acmd@homeoffice.gov.uk by Friday 31 July.
You should include a brief description of the organisation you represent, and the type of information you can provide.
The ACMD are particularly interested in hearing about prevalence of use and health and social harms relating to non-medical use of modafinil, methylphenidate and dexamfetamine in the following:
- school and university student populations
- competitive sporting environments
- workplace environments